...a 59-year-old female with a FGFR2-ZMYM4 fusion-positive ICC who presented with a dominant 15 cm liver mass and metastases to her liver and lungs...Upon next line TAS-120 treatment, she achieved stable disease with a best response of +8%. Progression occurred at approximately 7 months, with a mixed response consisting of rebound growth of a previously responsive lung lesion, stability of the dominant mass, and continued progression of the biopsied left lobe liver lesion.